Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/2702
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP-
dc.contributor.authorTRUDES, Guilherme-
dc.contributor.authorAIKAWA, Nadia E.-
dc.contributor.authorCAMPOS, Lucia M.-
dc.contributor.authorPEREIRA, Rosa M. R.-
dc.contributor.authorMORAES, Julio C. B.-
dc.contributor.authorRIBEIRO, Ana Cristina-
dc.contributor.authorMIRAGLIA, Joao-
dc.contributor.authorTIMENETSKY, Maria do Carmo S.-
dc.contributor.authorBONFA, Eloisa-
dc.contributor.authorSILVA, Clovis Artur-
dc.date.accessioned2013-10-11T21:16:38Z-
dc.date.available2013-10-11T21:16:38Z-
dc.date.issued2012-
dc.identifier.citationARTHRITIS AND RHEUMATISM, v.64, n.10, suppl.S, p.S847-S848, 2012-
dc.identifier.issn0004-3591-
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/2702-
dc.description.abstractBackground/Purpose: In 2010 the Advisory Committee on Immunization Practices from the CDC recommended that all children should receive the rivalent seasonal influenza vaccine containing the A/California/7/2009 (H1N1)-like virus with a specific protocol of two doses in subjects under 9 years old. There is, however, no data regarding this vaccine immunogenicity and safety in young children with autoimmune rheumatic diseases (ARD). Methods: 42 ARD patients and 12 healthy controls were initially recruited. One juvenile idiopathic arthritis patient had typical uncomplicated febrile seizure after first dose and did not receive the second dose and 3 patients and one control did not complete the study. Therefore, 38 ARD patients [25 juvenile idiopathic arthritis, 5 juvenile dermatomyositis, 3 juvenile systemic lupus erythematosus, 3 juvenile scleroderma and 2 primary vasculitis] and 11 healthy children completed the study and received two doses of a non-adjuvanted preparation of influenza A/California/7/2009 (H1N1) virus-like vaccine. They were clinically evaluated before and 21 days after the second dose of vaccination and serology for anti-H1N1 antibody was performed by hemagglutination inhibition (HI) assay. Seroprotection and seroconversion rates, geometric mean titres (GMT) and factor increase (FI) in GMT (ratio of the GMT after vaccination to the GMT before vaccination) were calculated. Adverse events were also evaluated. Results: Current age (7 vs. 7.8 years, p=0.55) and female gender (76. vs. 63.6%, p=0.45) were comparable in ARD patients and controls. Five (13.2%) patients were not receiving any drug, 18 (47.4%) patients were under non-steroidal anti-inflammatory drugs and 11 (28.9%) under prednisone, with a median current dose of 15mg (4–40). Twenty-three (60.5%) were taking methotrexate, 6 (15.8%) cyclosporine, one (2.6%) azathioprine and 7 (18.4%) anti-TNF agents. Pre-vaccination seroprotection rates (p=1.0) and GMT (p=0.63) were comparable between patients and controls. Three weeks after immunization seroprotection (81.6 vs. 81.8%; p=1.0), seroconversion rates (81.6 vs. 90.9%; p=0.66), GMT (151.5 vs. 282.1, p=0.26) and the FI in GMT (16.7 vs. 36.3; p=0.226) were similar in patients and controls, with both groups achieving adequate response according to the European Medicines Agency and Food and Drug Administration standards. The analysis of the possible factors influencing seroconversion showed no difference in demographic data, leukocytes and lymphocytes count or frequency of immunosuppressive drugs use (including prednisone, methotrexate, cyclosporine, azathioprine and anti-TNF agents) between seroconverted and non-seroconverted patients (p> 0.05). No severe adverse events were observed. Conclusion: Two doses of the non-adjuvanted influenza A H1N1/2009 vaccination induced an effective antibody response in young children with ARD independent of demographic characteristics, lymphocytes count and immunosuppressive treatment. Adverse events were rarely observed suggesting vaccine recommendation for this group of patients. (ClinicalTrials.gov,#NCT01151644)-
dc.language.isoeng-
dc.publisherWILEY-BLACKWELL-
dc.relation.ispartofArthritis and Rheumatism-
dc.rightsrestrictedAccess-
dc.titleImmunogenicity and Safety of Two Doses of Influenza A H1N1/2009 Vaccine in Young Autoimmune Rheumatic Diseases Patients Under 9 Years Old-
dc.typeconferenceObject-
dc.rights.holderCopyright WILEY-BLACKWELL-
dc.description.conferencedateNOV 09-14, 2012-
dc.description.conferencelocalWashington - DC, EUA-
dc.description.conferencenameAnnual Scientific Meeting of the American-College-of-Rheumatology (ACR) and Association-of-Rheumatology-Health-Professionals (ARHP)-
dc.identifier.doi10.1002/art.37735-
dc.subject.wosRheumatology-
dc.type.categorymeeting abstract-
dc.type.versionpublishedVersion-
hcfmusp.author.externalMIRAGLIA, Joao:Fundacao Butantan, Sao Paulo, Brazil-
hcfmusp.author.externalTIMENETSKY, Maria do Carmo S.:Univ Sao Paulo, Fac Med, Inst Adolfo Lutz, Sao Paulo, Brazil-
hcfmusp.author.externalSILVA, Clovis Artur:Ist Giannina Gaslini, Paediat Rheumatol Int Trials Org PRINTO, I-16148 Genoa, Italy-
hcfmusp.description.beginpageS847-
hcfmusp.description.endpageS848-
hcfmusp.description.issue10-
hcfmusp.description.issuesuppl S-
hcfmusp.description.volume64-
hcfmusp.origemWOS-
hcfmusp.origem.idWOS:000309748304276-
hcfmusp.publisher.cityHOBOKEN-
hcfmusp.publisher.countryUSA-
dc.description.indexMEDLINE-
Appears in Collections:

Comunicações em Eventos - FM/MCM
Departamento de Clínica Médica - FM/MCM

Comunicações em Eventos - HC/ICHC
Instituto Central - HC/ICHC

Comunicações em Eventos - HC/ICr
Instituto da Criança - HC/ICr

Comunicações em Eventos - LIM/17
LIM/17 - Laboratório de Investigação em Reumatologia

Comunicações em Eventos - LIM/36
LIM/36 - Laboratório de Pediatria Clínica


Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.